Maj Vinberg

List of Publications by Year
in descending order

233 papers	8,824 citations	50170 46 h-index	60497 81 g-index
256 all docs	256 docs citations	256 times ranked	8852 citing authors

#	Article	IF	Citations
1	Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2022, 101, 93-135.	2.0	670
2	Bipolar disorders. Lancet, The, 2020, 396, 1841-1856.	6.3	419
3	Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. Journal of Psychiatric Research, 2013, 47, 1119-1133.	1.5	358
4	Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. Psychoneuroendocrinology, 2010, 35, 1275-1286.	1.3	247
5	Cytokines in bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2013, 144, 16-27.	2.0	229
6	Designing mobile health technology for bipolar disorder. , 2013, , .		206
7	Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. Brain Research Bulletin, 2007, 73, 143-149.	1.4	178
8	Voice analysis as an objective state marker in bipolar disorder. Translational Psychiatry, 2016, 6, e856-e856.	2.4	167
9	Smartphone data as objective measures of bipolar disorder symptoms. Psychiatry Research, 2014, 217, 124-127.	1.7	162
10	Validity of the diagnosis of a single depressive episode in a case register. Clinical Practice and Epidemiology in Mental Health, 2009, 5, 4.	0.6	161
11	Antiâ€inflammatory agents in the treatment of bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2016, 18, 89-101.	1.1	153
12	Daily electronic self-monitoring in bipolar disorder using smartphones â€" the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial. Psychological Medicine, 2015, 45, 2691-2704.	2.7	152
13	Smartphone data as an electronic biomarker of illness activity in bipolar disorder. Bipolar Disorders, 2015, 17, 715-728.	1.1	131
14	Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Molecular Psychiatry, 2016, 21, 216-228.	4.1	120
15	The Bipolar Illness Onset study: research protocol for the BIO cohort study. BMJ Open, 2017, 7, e015462.	0.8	119
16	The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder. CNS Drugs, 2015, 29, 577-589.	2.7	113
17	Behavioral activities collected through smartphones and the association with illness activity in bipolar disorder. International Journal of Methods in Psychiatric Research, 2016, 25, 309-323.	1.1	113
18	Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. Journal of Affective Disorders, 2016, 205, 378-386.	2.0	110

#	Article	IF	Citations
19	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. Journal of Affective Disorders, 2017, 207, 114-120.	2.0	110
20	Cognitive function in unaffected twins discordant for affective disorder. Psychological Medicine, 2006, 36, 1119-1129.	2.7	107
21	Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Brain, Behavior, and Immunity, 2019, 75, 112-118.	2.0	103
22	Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. Nordic Journal of Psychiatry, 2012, 66, 248-253.	0.7	102
23	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neuroscience and Biobehavioral Reviews, 2018, 94, 11-16.	2.9	102
24	Effects of Short-Term Cognitive Remediation on Cognitive Dysfunction in Partially or Fully Remitted Individuals with Bipolar Disorder: Results of a Randomised Controlled Trial. PLoS ONE, 2015, 10, e0127955.	1.1	91
25	Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. Neuropsychopharmacology, 2014, 39, 1399-1408.	2.8	89
26	The effect of prolonged duration of untreated depression on antidepressant treatment outcome. Journal of Affective Disorders, 2013, 145, 42-48.	2.0	85
27	The search for neuroimaging and cognitive endophenotypes: A critical systematic review of studies involving unaffected first-degree relatives of individuals with bipolar disorder. Neuroscience and Biobehavioral Reviews, 2017, 73, 1-22.	2.9	85
28	Interaction between genetic polymorphisms and stressful life events in first episode depression. Journal of Affective Disorders, 2009, 119, 107-115.	2.0	84
29	Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders. Biological Psychiatry, 2015, 78, 270-277.	0.7	83
30	Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphonesâ€" the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. BMC Psychiatry, 2014, 14, 309.	1.1	82
31	Recombinant Human Erythropoietin to Target Cognitive Dysfunction in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, 1347-1355.	1.1	80
32	The effect of smartphone-based monitoring on illness activity in bipolar disorder: the MONARCA II randomized controlled single-blinded trial. Psychological Medicine, 2020, 50, 838-848.	2.7	75
33	Do personality traits predict first onset in depressive and bipolar disorder?. Nordic Journal of Psychiatry, 2006, 60, 79-88.	0.7	73
34	Daily electronic self-monitoring of subjective and objective symptoms in bipolar disorderâ€"the MONARCA trial protocol (MONitoring, treAtment and pRediCtion of bipolAr disorder episodes): a randomised controlled single-blind trial. BMJ Open, 2013, 3, e003353.	0.8	73
35	Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain, Behavior, and Immunity, 2015, 43, 205-213.	2.0	73
36	Differences in psychomotor activity in patients suffering from unipolar and bipolar affective disorder in the remitted or mild/moderate depressive state. Journal of Affective Disorders, 2012, 141, 457-463.	2.0	71

#	Article	IF	Citations
37	Hippocampal volume changes in healthy subjects at risk of unipolar depression. Journal of Psychiatric Research, 2010, 44, 655-662.	1.5	70
38	Assessment of subjective and objective cognitive function in bipolar disorder: Correlations, predictors and the relation to psychosocial function. Psychiatry Research, 2015, 229, 565-571.	1.7	67
39	Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder â€" Results from a prospective study. Journal of Affective Disorders, 2016, 197, 167-174.	2.0	67
40	Objective smartphone data as a potential diagnostic marker of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 119-128.	1.3	66
41	A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. Translational Psychiatry, 2015, 5, e614-e614.	2.4	58
42	Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology, 2012, 219, 687-698.	1.5	56
43	Differences Between Early and Late Onset Adult Depression. Clinical Practice and Epidemiology in Mental Health, 2011, 7, 140-147.	0.6	55
44	The catecholâ€Oâ€methyltransferase (*COMT*) Val158Met genotype modulates working memoryâ€related dorsolateral prefrontal response and performance in bipolar disorder. Bipolar Disorders, 2017, 19, 214-224.	1.1	54
45	Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. Bipolar Disorders, 2015, 17, 257-268.	1.1	51
46	High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. NeuroImage, 2009, 46, 360-366.	2.1	50
47	Mood instability in bipolar disorder type I versus type II-continuous daily electronic self-monitoring of illness activity using smartphones. Journal of Affective Disorders, 2015, 186, 342-349.	2.0	50
48	Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding. Neuropsychopharmacology, 2010, 35, 1129-1137.	2.8	49
49	Treatment with a GLPâˆ'1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. European Neuropsychopharmacology, 2017, 27, 1153-1162.	0.3	49
50	Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. Journal of Affective Disorders, 2012, 136, 134-138.	2.0	47
51	The BDNF Val66Met polymorphism: Relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Psychoneuroendocrinology, 2009, 34, 1380-1389.	1.3	46
52	Personalized medicine in psychiatry. Nordic Journal of Psychiatry, 2017, 71, 12-19.	0.7	46
53	Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology, 2014, 47, 199-211.	1.3	45
54	The effect of erythropoietin on cognition in affective disorders â€" Associations with baseline deficits and change in subjective cognitive complaints. European Neuropsychopharmacology, 2016, 26, 1264-1273.	0.3	45

#	Article	IF	Citations
55	From items to syndromes in the Hypomania Checklist (HCL-32): Psychometric validation and clinical validity analysis. Journal of Affective Disorders, 2011, 132, 48-54.	2.0	43
56	Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials, 2010, 11, 97.	0.7	42
57	Increased DNA and RNA damage by oxidation in patients with bipolar I disorder. Translational Psychiatry, 2016, 6, e867-e867.	2.4	42
58	The Influence of Comorbid Personality Disorder and Neuroticism on Treatment Outcome in First Episode Depression. Psychopathology, 2010, 43, 197-204.	1.1	41
59	The role of estrogen in bipolar disorder, a review. Nordic Journal of Psychiatry, 2014, 68, 81-87.	0.7	41
60	Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative. International Journal of Bipolar Disorders, 2019, 7, 20.	0.8	41
61	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disorders, 2020, 22, 831-840.	1.1	40
62	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. International Journal of Bipolar Disorders, 2019, 7, 8.	0.8	39
63	State€related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disorders, 2012, 14, 684-696.	1.1	38
64	Targeting Treatments to Improve Cognitive Function in Mood Disorder. Journal of Clinical Psychiatry, 2016, 77, e1639-e1646.	1.1	37
65	Internet use by patients with bipolar disorder: Results from an international multisite survey. Psychiatry Research, 2016, 242, 388-394.	1.7	36
66	Online information seeking by patients with bipolar disorder: results from an international multisite survey. International Journal of Bipolar Disorders, 2016, 4, 17.	0.8	35
67	The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project. Therapeutic Advances in Chronic Disease, 2016, 7, 153-159.	1.1	35
68	Remitted affective disorders and high familial risk of affective disorders associate with aberrant intestinal microbiota. Acta Psychiatrica Scandinavica, 2019, 139, 174-184.	2.2	35
69	Neural correlates of improved executive function following erythropoietin treatment in mood disorders. Psychological Medicine, 2016, 46, 1679-1691.	2.7	34
70	Neural response during emotion regulation in monozygotic twins at high familial risk of affective disorders. NeuroImage: Clinical, 2019, 21, 101598.	1.4	34
71	Impairment of Executive Function and Attention Predicts Onset of Affective Disorder in Healthy High-Risk Twins. Journal of Clinical Psychiatry, 2013, 74, e747-e753.	1.1	34
72	Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 300, 449-461.	2.0	34

#	Article	IF	Citations
73	Different neural and cognitive response to emotional faces in healthy monozygotic twins at risk of depression. Psychological Medicine, 2015, 45, 1447-1458.	2.7	32
74	Is smartphone‐based mood instability associated with stress, quality of life, and functioning in bipolar disorder?. Bipolar Disorders, 2019, 21, 611-620.	1.1	32
75	No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. European Neuropsychopharmacology, 2010, 20, 327-335.	0.3	31
76	Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. CNS Spectrums, 2016, 21, 362-366.	0.7	31
77	Cerebrospinal fluid oxidative stress metabolites in patients with bipolar disorder and healthy controls: a longitudinal case-control study. Translational Psychiatry, 2019, 9, 325.	2.4	31
78	Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2019, 53, 651-662.	1.3	31
79	Effect of Action‐Based Cognitive Remediation on cognitive impairment in patients with remitted bipolar disorder: A randomized controlled trial. Bipolar Disorders, 2021, 23, 487-499.	1.1	31
80	Whole blood BDNF levels in healthy twins discordant for affective disorder: Association to life events and neuroticism. Journal of Affective Disorders, 2008, 108, 165-169.	2.0	30
81	Salivary cortisol in unaffected twins discordant for affective disorder. Psychiatry Research, 2008, 161, 292-301.	1.7	30
82	Effects of cognitive remediation on cognitive dysfunction in partially or fully remitted patients with bipolar disorder: study protocol for a randomized controlled trial. Trials, 2013, 14, 378.	0.7	29
83	Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study. International Journal of Bipolar Disorders, 2019, 7, 5.	0.8	29
84	Does bereavement-related first episode depression differ from other kinds of first depressions?. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 801-808.	1.6	27
85	Clinical utility of Standardised Assessment of Personality â€" Abbreviated Scale (SAPAS) among patients with first episode depression. Journal of Affective Disorders, 2010, 127, 199-202.	2.0	27
86	Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder?. Nordic Journal of Psychiatry, 2012, 66, 389-395.	0.7	27
87	Effects of erythropoietin on memory‐relevant neurocircuitry activity and recall in mood disorders. Acta Psychiatrica Scandinavica, 2016, 134, 249-259.	2.2	27
88	State-related differences in the level of psychomotor activity in patients with bipolar disorderÂâ€" Continuous heart rate and movement monitoring. Psychiatry Research, 2016, 237, 166-174.	1.7	27
89	Differences in clinical presentation between bipolar I and II disorders in the early stages of bipolar disorder: A naturalistic study. Journal of Affective Disorders, 2017, 208, 521-527.	2.0	26
90	Risk of recurrence after a single manic or mixed episode â€" a systematic review and metaâ€analysis. Bipolar Disorders, 2018, 20, 9-17.	1.1	26

#	Article	IF	Citations
91	Neurocognitive heterogeneity in patients with bipolar disorder and their unaffected relatives: associations with emotional cognition. Psychological Medicine, 2021, 51, 668-679.	2.7	26
92	Development and implementation of guidelines for the management of depression: a systematic review. Bulletin of the World Health Organization, 2020, 98, 683-697H.	1.5	25
93	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. Journal of Affective Disorders, 2021, 282, 160-164.	2.0	24
94	Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials. Nordic Journal of Psychiatry, 2013, 67, 369-382.	0.7	23
95	Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: A pilot study of a novel experimental paradigm. Psychiatry Research, 2016, 238, 318-325.	1.7	23
96	A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder. Acta Psychiatrica Scandinavica, 2019, 139, 227-236.	2.2	23
97	Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives. Psychoneuroendocrinology, 2019, 99, 183-190.	1.3	23
98	Mood instability in patients with newly diagnosed bipolar disorder, unaffected relatives, and healthy control individuals measured daily using smartphones. Journal of Affective Disorders, 2020, 271, 336-344.	2.0	23
99	Risk markers for affective disorder, a seven-years follow up study of a twin cohort at low and high risk for affective disorder. Journal of Psychiatric Research, 2013, 47, 565-571.	1.5	22
100	Reduced mRNA Expression of PTGDS in Peripheral Blood Mononuclear Cells of Rapid-Cycling Bipolar Disorder Patients Compared with Healthy Control Subjects. International Journal of Neuropsychopharmacology, 2015, 18, pyu101-pyu101.	1.0	22
101	Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study. Brain, Behavior, and Immunity, 2016, 57, 53-57.	2.0	22
102	Aberrant cognition in newly diagnosed patients with bipolar disorder and their unaffected relatives. Psychological Medicine, 2020, 50, 1808-1819.	2.7	22
103	A nation-wide population-based longitudinal study mapping physical diseases in patients with bipolar disorder and their siblings. Journal of Affective Disorders, 2021, 282, 18-25.	2.0	22
104	Do stressful life events predict medical treatment outcome in first episode of depression?. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 752-760.	1.6	20
105	Dose-remission of pulsating electromagnetic fields as augmentation in therapy-resistant depression: a randomized, double-blind controlled study. Acta Neuropsychiatrica, 2014, 26, 272-279.	1.0	20
106	Brain‐derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disorders, 2016, 18, 373-378.	1.1	20
107	The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression—A randomised trial. Psychiatry Research, 2012, 200, 354-360.	1.7	19
108	Influences of patient informed cognitive complaints on activities of daily living in patients with bipolar disorder. An exploratory cross-sectional study. Psychiatry Research, 2017, 249, 268-274.	1.7	19

#	Article	IF	Citations
109	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. European Neuropsychopharmacology, 2019, 29, 137-146.	0.3	19
110	Peripheral inflammatory biomarkers define biotypes of bipolar depression. Molecular Psychiatry, 2021, 26, 3395-3406.	4.1	19
111	Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression. Advances in Therapy, 2021, 38, 2795-2820.	1.3	19
112	The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study. PLoS ONE, 2015, 10, e0127629.	1.1	18
113	Sexual distress and quality of life among women with bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 29.	0.8	18
114	Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial. Trials, 2018, 19, 487.	0.7	18
115	Socio-economic functioning in patients with bipolar disorder and their unaffected siblings – results from a nation-wide population-based longitudinal study. Psychological Medicine, 2023, 53, 706-713.	2.7	18
116	Smartphone-based activity measurements in patients with newly diagnosed bipolar disorder, unaffected relatives and control individuals. International Journal of Bipolar Disorders, 2020, 8, 32.	0.8	17
117	Personality traits in unaffected twins discordant for affective disorder. Acta Psychiatrica Scandinavica, 2007, 115, 442-450.	2.2	16
118	Variations in 5-HTTLPR: Relation to familiar risk of affective disorder, life events, neuroticism and cortisol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 86-91.	2.5	16
119	Electronic monitoring of psychomotor activity as a supplementary objective measure of depression severity. Nordic Journal of Psychiatry, 2015, 69, 118-125.	0.7	16
120	Increased blood BDNF in healthy individuals with a family history of depression. Psychiatry Research, 2017, 256, 176-179.	1.7	16
121	Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials, 2018, 19, 611.	0.7	16
122	Does S100B have a potential role in affective disorders? A literature review. Nordic Journal of Psychiatry, 2018, 72, 462-470.	0.7	16
123	Daily mobility patterns in patients with bipolar disorder and healthy individuals. Journal of Affective Disorders, 2021, 278, 413-422.	2.0	16
124	Affective disorders impact prevalence of Flavonifractor and abundance of Christensenellaceae in gut microbiota. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110300.	2.5	15
125	Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression?. Psychiatry Research, 2013, 210, 102-108.	1.7	14
126	Towards a biomarker model for cognitive improvement: No change in memory-related prefrontal engagement following a negative cognitive remediation trial in bipolar disorder. Journal of Psychopharmacology, 2018, 32, 1075-1085.	2.0	14

#	Article	IF	Citations
127	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials, 2009, 10, 66.	0.7	13
128	Gender Differences among Patients with a Single Depressive Episode. Psychopathology, 2010, 43, 159-169.	1.1	13
129	Effect of Chronic Escitalopram versus Placebo on Personality Traits in Healthy First-Degree Relatives of Patients with Depression: A Randomized Trial. PLoS ONE, 2012, 7, e31980.	1.1	13
130	Risk for affective disorders is associated with greater prefrontal gray matter volumes: A prospective longitudinal study. NeuroImage: Clinical, 2018, 17, 786-793.	1.4	13
131	Internet use by older adults with bipolar disorder: international survey results. International Journal of Bipolar Disorders, 2018, 6, 20.	0.8	13
132	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients â€" A Randomized Placebo-Controlled Trial. PLoS ONE, 2011, 6, e21224.	1.1	12
133	Leukocytes in peripheral blood in patients with bipolar disorder â€" Trait and state alterations and association with levels of cytokines and C-reactive protein. Psychiatry Research, 2018, 261, 383-390.	1.7	12
134	Is aberrant affective cognition an endophenotype for affective disorders? â€" A monozygotic twin study. Psychological Medicine, 2019, 49, 987-996.	2.7	12
135	The association between mixed symptoms, irritability and functioning measured using smartphones in bipolar disorder. Acta Psychiatrica Scandinavica, 2019, 139, 443-453.	2.2	12
136	Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? â€" a monozygotic twin study. Psychological Medicine, 2020, 50, 1736-1745.	2.7	12
137	Higher systemic oxidatively generated DNA and RNA damage in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Free Radical Biology and Medicine, 2021, 168, 226-233.	1.3	12
138	A nation-wide population-based longitudinal study on life expectancy and cause specific mortality in patients with bipolar disorder and their siblings. Journal of Affective Disorders, 2021, 294, 472-476.	2.0	12
139	Bipolar Patients' Quality of Life in Mixed States: A Preliminary Qualitative Study. Psychopathology, 2015, 48, 192-201.	1.1	11
140	Differences in neural and cognitive response to emotional faces in middle-aged dizygotic twins at familial risk of depression. Psychological Medicine, 2017, 47, 2345-2357.	2.7	11
141	Substance use among Danish psychiatric patients: a cross-sectional study. Nordic Journal of Psychiatry, 2018, 72, 130-136.	0.7	11
142	Clinical Characteristics, Life Adversities and Personality Traits in Monozygotic Twins With, at Risk of and Without Affective Disorders. Frontiers in Psychiatry, 2018, 9, 401.	1.3	11
143	A nationwide populationâ€based longitudinal study mapping psychiatric disorders during lifetime in siblings to patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2021, 143, 284-293.	2.2	11
144	Increased sensitivity to positive social stimuli in monozygotic twins at risk of bipolar vs. unipolar disorder. Journal of Affective Disorders, 2018, 232, 212-218.	2.0	10

#	Article	IF	Citations
145	Is negative self-referent bias an endophenotype for depression? An fMRI study of emotional self-referent words in twins at high vs. low risk of depression. Journal of Affective Disorders, 2018, 226, 267-273.	2.0	10
146	Effects of erythropoietin on body composition and fat–glucose metabolism in patients with affective disorders. Acta Neuropsychiatrica, 2018, 30, 342-349.	1.0	10
147	The impact of the trajectory of bipolar disorder on global cognitive function: A one-year clinical prospective case-control study. Journal of Affective Disorders, 2021, 278, 189-198.	2.0	10
148	Sleep and physical activity in patients with newly diagnosed bipolar disorder in remission, their first-degree unaffected relatives and healthy controls. International Journal of Bipolar Disorders, 2020, 8, 16.	0.8	10
149	Brain Derived Neurotrophic Factor (BDNF) levels as a possible predictor of psychopathology in healthy twins at high and low risk for affective disorder. Psychoneuroendocrinology, 2014, 39, 179-183.	1.3	9
150	The Diagnostic Apathia Scale predicts a dose–remission relationship of T-PEMF in treatment-resistant depression. Acta Neuropsychiatrica, 2015, 27, 1-7.	1.0	9
151	The validity of daily patient-reported anxiety measured using smartphones and the association with stress, quality of life and functioning in patients with bipolar disorder. Journal of Affective Disorders, 2019, 257, 100-107.	2.0	9
152	Reduced frontostriatal response to expected value and reward prediction error in remitted monozygotic twins with mood disorders and their unaffected high-risk co-twins. Psychological Medicine, 2021, 51, 1637-1646.	2.7	9
153	Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study. European Psychiatry, 2020, 63, e18.	0.1	9
154	Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls. BJPsych Open, 2021, 7, e55.	0.3	9
155	Emotional cognition subgroups in mood disorders: Associations with familial risk. European Neuropsychopharmacology, 2021, 51, 71-83.	0.3	9
156	Coping Styles in Healthy Individuals at Risk of Affective Disorder. Journal of Nervous and Mental Disease, 2010, 198, 39-44.	0.5	8
157	A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression. Therapeutic Advances in Psychopharmacology, 2011, 1, 133-144.	1.2	8
158	Glycogen synthase kinase–3β in patients with bipolar I disorder: results from a prospective study. Bipolar Disorders, 2016, 18, 334-341.	1.1	8
159	Affective episodes in recently diagnosed patients with bipolar disorder associated with altered working memory-related prefrontal cortex activity: A longitudinal fMRI study. Journal of Affective Disorders, 2021, 295, 647-656.	2.0	8
160	Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials, 2018, 19, 234.	0.7	7
161	Associations between the cortisol awakening response and patient-evaluated stress and mood instability in patients with bipolar disorder: an exploratory study. International Journal of Bipolar Disorders, 2021, 9, 8.	0.8	7
162	Healthy co-twins of patients with affective disorders show reduced risk-related activation of the insula during a monetary gambling task. Journal of Psychiatry and Neuroscience, 2016, 41, 38-47.	1.4	7

#	Article	IF	Citations
163	Voice analyses using smartphone-based data in patients with bipolar disorder, unaffected relatives and healthy control individuals, and during different affective states. International Journal of Bipolar Disorders, 2021, 9, 38.	0.8	7
164	Socio-economic status and functioning in patients newly diagnosed with bipolar disorder and their unaffected siblings - Results from a cross-sectional clinical study. Journal of Affective Disorders, 2022, 310, 404-411.	2.0	7
165	Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. Nordic Journal of Psychiatry, 2012, 66, 142-145.	0.7	6
166	The Performance of the Revised Major Depression Inventory for Self-Reported Severity of Depression - Implications for the DSM-5 and ICD-11. Psychotherapy and Psychosomatics, 2013, 82, 187-188.	4.0	6
167	No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial. Acta Neuropsychiatrica, 2016, 28, 101-109.	1.0	6
168	Unaffected twins discordant for affective disorders show changes in anterior callosal white matter microstructure. Acta Psychiatrica Scandinavica, 2016, 134, 441-451.	2.2	6
169	Mood, activity, and sleep measured via daily smartphone-based self-monitoring in young patients with newly diagnosed bipolar disorder, their unaffected relatives and healthy control individuals. European Child and Adolescent Psychiatry, 2021, 30, 1209-1221.	2.8	6
170	Daily self-reported and automatically generated smartphone-based sleep measurements in patients with newly diagnosed bipolar disorder, unaffected first-degree relatives and healthy control individuals. Evidence-Based Mental Health, 2020, 23, 146-153.	2.2	6
171	Hypomania/Mania by DSM-5 definition based on daily smartphone-based patient-reported assessments. Journal of Affective Disorders, 2020, 264, 272-278.	2.0	6
172	Cognitive processing of infant stimuli in pregnant women with and without affective disorders and the association to postpartum depression. European Neuropsychopharmacology, 2021, 42, 97-109.	0.3	6
173	Neural underpinnings of emotion regulation subgroups in remitted patients with recently diagnosed bipolar disorder. European Neuropsychopharmacology, 2022, 60, 7-18.	0.3	6
174	Serotonin transporter genotype, salivary cortisol, neuroticism and life events: Impact on subsequent psychopathology in healthy twins at high and low risk for affective disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 193-198.	2.5	5
175	Glycogen Synthase Kinase-3β: Variation over Time and the Possible Association with Mood and Cognition in Healthy Individuals. Neuropsychobiology, 2016, 73, 108-115.	0.9	5
176	Neural correlates of improved recognition of happy faces after erythropoietin treatment in bipolar disorder. Acta Psychiatrica Scandinavica, 2018, 138, 336-347.	2.2	5
177	Emotional Mental Imagery Abnormalities in Monozygotic Twins With, at High-Risk of, and Without Affective Disorders: Present in Affected Twins in Remission but Absent in High-Risk Twins. Frontiers in Psychiatry, 2019, 10, 801.	1.3	5
178	Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial. Journal of Psychiatry and Neuroscience, 2020, 45, 198-205.	1.4	5
179	Ability to perform Activities of Daily Living among patients with bipolar disorder in remission. Edorium Journal of Disability and Rehabilitation, 2017, 3, 3.	0.3	5
180	Patient-evaluated cognitive function measured with smartphones and the association with objective cognitive function, perceived stress, quality of life and function capacity in patients with bipolar disorder. International Journal of Bipolar Disorders, 2020, 8, 31.	0.8	5

#	Article	IF	Citations
181	Physical Health Profile and Associated Behavior During the COVID-19 Pandemic in Patients With Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 759694.	1.3	5
182	Attention to side effects enhances medical adherence. Acta Psychiatrica Scandinavica, 2007, 115, 82-82.	2.2	4
183	Quality of life in unaffected twins discordant for affective disorder. Journal of Affective Disorders, 2007, 99, 133-138.	2.0	4
184	Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression â€" a secondary outcome analysis from the randomized AGENDA trial. Nordic Journal of Psychiatry, 2016, 70, 297-302.	0.7	4
185	International multi-site survey on the use of online support groups in bipolar disorder. Nordic Journal of Psychiatry, 2017, 71, 473-476.	0.7	4
186	Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder. European Neuropsychopharmacology, 2018, 28, 361-368.	0.3	4
187	Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. Evidence-Based Mental Health, 2020, 23, 2-7.	2.2	4
188	S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. Journal of Affective Disorders, 2020, 274, 726-732.	2.0	4
189	Abnormal prefrontal cortex processing of reward prediction errors in recently diagnosed patients with bipolar disorder and their unaffected relatives. Bipolar Disorders, 2020, 22, 849-859.	1.1	4
190	Hippocampal subfield morphology in monozygotic twins discordant for affective disorders. Neuropsychopharmacology, 2021, 46, 561-568.	2.8	4
191	Affective and non-affective cognition in patients with bipolar disorder type I and type II in full or partial remission: Associations with familial risk. Journal of Affective Disorders, 2021, 283, 207-215.	2.0	4
192	Impact of modification to DSM-5 criterion A for hypomania/mania in newly diagnosed bipolar patients: findings from the prospective BIO study. International Journal of Bipolar Disorders, 2021, 9, 14.	0.8	4
193	Neural response to emotional faces in monozygotic twins: association with familial risk of affective disorders. Journal of Psychiatry and Neuroscience, 2019, 44, 277-286.	1.4	4
194	Trajectory of aberrant reward processing in patients with bipolar disorder â€" A longitudinal fMRI study. Journal of Affective Disorders, 2022, 312, 235-244.	2.0	4
195	Searching for the Needles in a Haystack; Is It Needless? The Search for Peripheral Biomarkers in Psychiatry. Frontiers in Psychiatry, 2020, 11, 689.	1.3	3
196	Automatically Generated Smartphone Data in Young Patients With Newly Diagnosed Bipolar Disorder and Healthy Controls. Frontiers in Psychiatry, 2021, 12, 559954.	1.3	3
197	Effect of specialised versus generalised outpatient treatment for bipolar disorder: the CAG Bipolar trial - study protocol for a randomised controlled trial. BMJ Open, 2021, 11, e048821.	0.8	3
198	Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives â€" A longitudinal study. Journal of Affective Disorders, 2022, 311, 115-125.	2.0	3

#	ARTICLE	IF	CITATIONS
199	Whole-Brain Exploratory Analysis of Functional Task Response Following Erythropoietin Treatment in Mood Disorders: A Supervised Machine Learning Approach. Frontiers in Neuroscience, 2019, 13, 1246.	1.4	2
200	The BDNF Val66Met Polymorphism Has No Effect on Encoding-Related Hippocampal Response But Influences Recall in Remitted Patients With Bipolar Disorder. Frontiers in Psychiatry, 2019, 10, 845.	1.3	2
201	Automatically generated smartphone data and subjective stress in healthy individuals â€" a pilot study. Nordic Journal of Psychiatry, 2020, 74, 293-300.	0.7	2
202	Association between lifetime and recent stressful life events and the early course and psychopathology in patients with newly diagnosed bipolar disorder, firstâ€degree unaffected relatives and healthy controls: Crossâ€sectional results from a prospective study. Bipolar Disorders, 2022, 24, 59-68.	1.1	2
203	Peripheral Inflammatory Biomarkers Define Biotypes of Bipolar Depression. Biological Psychiatry, 2021, 89, S156.	0.7	2
204	Prevalences of comorbid anxiety disorder and daily smartphone-based self-reported anxiety in patients with newly diagnosed bipolar disorder. Evidence-Based Mental Health, 2021, 24, 137-144.	2.2	2
205	High-sensitive C-reactive protein and homocysteine levels in patients with newly diagnosed bipolar disorder, their first-degree relatives, and healthy control personsâ€"Results from a clinical study. European Psychiatry, 2020, 63, e103.	0.1	2
206	Discriminating between patients with unipolar disorder, bipolar disorder, and healthy control individuals based on voice features collected from naturalistic smartphone calls. Acta Psychiatrica Scandinavica, 2022, 145, 255-267.	2.2	2
207	Psychometric validation and clinical validity of the Minor Melancholia Mood Checklist (MMCL-32). Journal of Affective Disorders, 2012, 137, 79-86.	2.0	1
208	A randomized placeboâ€controlled trial examining the effects of escitalopram on neuroticism and state anxiety in a nonclinical sample. Human Psychopharmacology, 2019, 34, e2711.	0.7	1
209	Thirty-year cardiovascular risk in patients with newly diagnosed bipolar disorder and their healthy first-degree relatives. European Neuropsychopharmacology, 2019, 29, S347-S348.	0.3	1
210	Residual Anxiety in Patients with Bipolar Disorder in Full or Partial Remission: Metacognitive Beliefs and Neurocognitive Function. Cognitive Therapy and Research, 2021, 45, 179-189.	1.2	1
211	Neural responses during down-regulation of negative emotion in patients with recently diagnosed bipolar disorder and their unaffected relatives. Psychological Medicine, 0, , 1-12.	2.7	1
212	Dr Miskowiak and Colleagues Reply. Journal of Clinical Psychiatry, 2015, 76, e835-e836.	1.1	1
213	Emotional cognition subgroups in unaffected first-degree relatives of patients with mood disorders. Psychological Medicine, 0, , 1-11.	2.7	1
214	Physical health status in first-degree relatives of patients with bipolar disorder, a systematic review. Nordic Journal of Psychiatry, 2022, 76, 433-441.	0.7	1
215	At the Core of Depression: A Diagnostic Interview of the Core Features of Depression. Psychopathology, 2022, 55, 219-225.	1.1	1
216	Subjective experience of cognitive function in affective disorders. European Psychiatry, 2011, 26, 234-234.	0.1	0

#	Article	IF	Citations
217	P.2.d.033 Erythropoetin as a new treatment for cogntive dysfunction in bipolar disorder?. European Neuropsychopharmacology, 2013, 23, S383.	0.3	0
218	A peripheral composite proteomic and gene expression biomarker related to diagnosis and affective state in rapid cycling bipolar disorder. European Psychiatry, 2016, 33, S123-S123.	0.1	0
219	Mogens Schou (1918â€2005): a scientist, a doctor and a lithium champion. Bipolar Disorders, 2018, 20, 680-682.	1.1	0
220	Hormones, Emotional processing and prepartum Attachment in Pregnant women with Affective Disorders (HEAPAD). European Neuropsychopharmacology, 2019, 29, S382.	0.3	0
221	P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders â€" a twin study. European Neuropsychopharmacology, 2019, 29, S706-S707.	0.3	0
222	P.654 Central oxidative stress of RNA damage in patients with bipolar disorder and healthy control individuals. A prospective longitudinal case-control study. European Neuropsychopharmacology, 2019, 29, S444.	0.3	0
223	P.357 S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. European Neuropsychopharmacology, 2019, 29, S255.	0.3	0
224	P.298 Emotional cognition heterogeneity in patients with mood disorders and clinical implication. European Neuropsychopharmacology, 2020, 40, S170-S171.	0.3	0
225	Misinformed, misconducted, misguided and misrepresented metaâ€analyses. The use of antidepressants (AD) in major depressive disorders (MDD). Bipolar Disorders, 2020, 22, 862-863.	1.1	0
226	Suicidal behaviour and bipolar disorder. , 2021, , 293-300.		0
227	P.319 Cognitive predictors of mood episodes in patients newly diagnosed with bipolar disorder. European Neuropsychopharmacology, 2021, 44, S52-S53.	0.3	0
228	Intrauterine testosterone exposure and depression risk in opposite-sex and same-sex twins, a Danish register study. Psychological Medicine, 2021, , 1-6.	2.7	0
229	Risk. Impact of having a first-degree relative with affective disorder: a 7-year follow-up study. Danish Medical Journal, 2016, 63, .	0.5	0
230	Pharmacological Treatment of Individuals at Familial Risk for Bipolar or Major Depressive Disorders: a Scoping Review. Current Treatment Options in Psychiatry, 0, , 1.	0.7	0
231	P.0717 Differential trajectory of cognitive functions in neurocognitive subgroups of newly diagnosed patients with bipolar disorder and their unaffected first-degree relatives. European Neuropsychopharmacology, 2021, 53, S524-S525.	0.3	0
232	P.0077 Higher systemic oxidatively generated DNA and RNA damage in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. European Neuropsychopharmacology, 2021, 53, S54-S55.	0.3	0
233	Affective disorders: eliminate WArning signs and REstore functioningâ€"AWAREâ€"a randomised controlled multimodule intervention study, presentation of design and intervention. BMJ Open, 2022, 12, e058839.	0.8	0